<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04941534</url>
  </required_header>
  <id_info>
    <org_study_id>AMBER</org_study_id>
    <nct_id>NCT04941534</nct_id>
  </id_info>
  <brief_title>This Clinical Study Evaluates the Performance and Safety of Biorithm Research Kit Versus CTG in Prenatal Monitoring of Pregnant Participants.</brief_title>
  <official_title>AMBulatory Fetal ECG Monitoring in High Risk Pregnancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biorithm Pte Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biorithm Pte Ltd</source>
  <brief_summary>
    <textblock>
      This clinical study will evaluate the safety and comparative performance of Biorithm Research&#xD;
      Kit vs CTG (gold standard) in prenatal monitoring of pregnant participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Biorithm Research Kit system used in this study consists of femom fetal monitor (known as&#xD;
      fetal monitor), a digital gateway and a cloud storage. It's intended for monitoring of&#xD;
      maternal and fetal physiological parameters. It includes non-invasive fetal monitor or&#xD;
      device, that monitors fetal heart rate (FHR), maternal heart rate (MHR), and uterine activity&#xD;
      (UA) in the antepartum period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fetal Heart Rate (FHR)</measure>
    <time_frame>40 minutes</time_frame>
    <description>FHR agreement between Biorithm Research Kit and standard of care (CTG)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maternal Heart Rate (MHR)</measure>
    <time_frame>40 minutes</time_frame>
    <description>MHR agreement between Biorithm Research Kit and standard of care (CTG)</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pregnancy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Participants would be recruited at the Day Assessment Unit who require CTG monitoring and&#xD;
        meet the inclusion criteria&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a singleton pregnancy&#xD;
&#xD;
          -  Should be at and above 28 weeks of pregnancy&#xD;
&#xD;
          -  Should have a valid indication for antenatal FHR monitoring as part of their pregnancy&#xD;
             management, as per local hospital policy&#xD;
&#xD;
          -  Able to speak English or have access to an interpreter and provide Informed Consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with an intellectual or mental impairment&#xD;
&#xD;
          -  Participants with a known allergy or hypersensitivity to ECG gel electrodes&#xD;
&#xD;
          -  Participants in pain, with contractions or in labour&#xD;
&#xD;
          -  Known fetal cardiac or genetic abnormality&#xD;
&#xD;
          -  Participant with a pacemaker&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Baskaran Thilaganathan</last_name>
    <role>Principal Investigator</role>
    <affiliation>St-George's University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Baskaran Thilaganathan</last_name>
    <phone>02087250072</phone>
    <email>basky.thilaganathan@nhs.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>St George's University Hospital</name>
      <address>
        <city>London</city>
        <zip>SW17ORE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Professor Basakaran Thilaganathan</last_name>
      <phone>02087250072</phone>
      <email>basky.thilaganathan@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 22, 2021</study_first_submitted>
  <study_first_submitted_qc>June 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2021</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antepartum monitoring</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

